BS_HTEPAKCM
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 36.24
- os_event
- false
- age_years
- 6.356
- sex
- M
- race
- White
- new_clusters
- C6
- umap1_2d
- 3.722022478
- umap2_2d
- 6.430568436
- umap1_3d
- 2.727142567
- umap2_3d
- -0.766830914
- umap3_3d
- -4.499044924
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.410
- PI3K_AKT_MTOR_SIGNALING+0.130
- HEME_METABOLISM+0.100
- NOTCH_SIGNALING+0.100
- MITOTIC_SPINDLE+0.090
- HEDGEHOG_SIGNALING+0.050
- SPERMATOGENESIS+0.040
- DNA_REPAIR+0.010
- PEROXISOME+0.010
- TNFA_SIGNALING_VIA_NFKB+0.010
Top 10 suppressed
- MYC_TARGETS_V2-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- ANGIOGENESIS-0.330
- ALLOGRAFT_REJECTION-0.320
- MYC_TARGETS_V1-0.300
- APICAL_SURFACE-0.290
- IL2_STAT5_SIGNALING-0.290
- INTERFERON_ALPHA_RESPONSE-0.290
- INTERFERON_GAMMA_RESPONSE-0.270
- COAGULATION-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3296 | Med | Medulloblastoma | 0.854 |
| 2 | MDT-AP-2017 | Med | Medulloblastoma | 0.834 |
| 3 | MDT-AP-0119 | Med | Medulloblastoma | 0.825 |
| 4 | MDT-AP-3207 | Med | Medulloblastoma | 0.825 |
| 5 | TCGA-A7-A13G-01A-11R-A13Q-07 | — | D | 0.819 |
| 6 | SRR12475149 | — | — | 0.817 |
| 7 | MDT-AP-0180 | Med | Medulloblastoma | 0.813 |
| 8 | MDT-AP-0364 | Med | Medulloblastoma | 0.810 |
| 9 | MDT-AP-2991 | Med | Medulloblastoma | 0.807 |
| 10 | R357 | — | — | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.010 | Inavolisib | — uncovered |